{"id":"mk-8237-tablets","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2057618","moleculeType":"Small molecule","molecularWeight":"164.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MK-8237 appears to function as an immune modulator that enhances or redirects immune responses against disease targets. The exact molecular mechanism remains proprietary, but the compound is being developed for conditions where immune system activation or rebalancing is therapeutically beneficial.","oneSentence":"MK-8237 is an oral immunotherapeutic agent designed to modulate immune responses, likely through toll-like receptor (TLR) signaling or related innate immune pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:21:40.871Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis and related allergic conditions (Phase 3)"}]},"trialDetails":[{"nctId":"NCT01852825","phase":"PHASE1","title":"MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-11-27","conditions":"Allergic Rhinitis, Allergic Rhinoconjunctivitis","enrollment":26},{"nctId":"NCT01644617","phase":"PHASE2","title":"A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2012-10","conditions":"Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal","enrollment":124},{"nctId":"NCT01700192","phase":"PHASE3","title":"Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2013-01","conditions":"Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal","enrollment":1482},{"nctId":"NCT01678807","phase":"PHASE1","title":"Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2012-10","conditions":"Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal","enrollment":195}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SCH 900237"],"phase":"phase_3","status":"active","brandName":"MK-8237 tablets","genericName":"MK-8237 tablets","companyName":"ALK-Abelló A/S","companyId":"alk-abell-a-s","modality":"Biologic","firstApprovalDate":"","aiSummary":"MK-8237 is an oral immunotherapeutic agent designed to modulate immune responses, likely through toll-like receptor (TLR) signaling or related innate immune pathways. Used for Allergic rhinitis and related allergic conditions (Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}